-
-
-
-
-
-
-
Atea presents hepatitis C drug data showing 7-8 week cure potential
-
-
-
-
-
-
-
Aviragen Therapeutics (AVIR) Misses Q4 EPS by 5c
-
-
-
-
-
-
-
Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) to Equalweight, 'HCV opportunity comes into focus, while COVID outcome remains uncertain'
-
-
456,923 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

